Molecular Partners Ag(MLLCF)

Description: Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.

---

Keywords: Biopharmaceutical Drugs Solid Tumors Tumor Partnership Cancer Immunotherapy Multiple Myeloma Macular Degeneration Wet Age Related Macular Degeneration Diabetic Macular Edema Macular Edema Restore Mge Vascular Endothelial Growth Factor Molecular Partners Darpin Abicipar Attack Tumors Her2 Positive Solid Tumors Mp0274 Vascular Endothelial Growth Factor A

---

Home Page: www.molecularpartners.com

Wagistrasse 14
Schlieren, 8952
Switzerland
Phone: 41 44 755 77 00

---

Officers

Exchange: PINK

Country: US

Currency: US Dollar ($)